N/A
N=944
Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment
Smoking Reduction · Tobacco Use · Tobacco Smoking · Tomography · Lung Diseases
Bottom Line
View on ClinicalTrials.gov: NCT03612804 ↗Enrolled (actual)
944
Serious AEs
—
Results posted
Oct 2024
Primary outcome: Primary: Self-reported Smoking Abstinence — 50; 51 Participants — p=0.83
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Unsigned note to provider about cessation medication prescription (Behavioral); Proactive Telephone Counseling from VA Quitline (Behavioral)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Feb 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Self-reported Smoking Abstinence |
50; 51 | 0.83 |
| SECONDARY Cost of Smoking Cessation Care |
34.1; 384.2 | — |
| SECONDARY Patients' Experience With Telephone Counseling |
34 | — |
| SECONDARY Patients' Motivational Assessment |
7.48; 7.3 | — |
| SECONDARY Patients' Perception of Susceptibility to Harm |
1.97; 2.09 | — |
| SECONDARY Patients' Self-efficacy Assessment |
5.8; 6.1 | — |
| SECONDARY Patients' Motivational Assessment |
7.48; 7.3 | — |
| SECONDARY Patients' Self-efficacy Assessment |
5.8; 6.1 | — |
Summary
This pragmatic trial will evaluate the value of routinely providing proactive smoking cessation support to current smokers as a part of participating in lung cancer screening within Veterans Health Administration.
Eligibility Criteria
Inclusion Criteria
- Providers who schedule patients for a lung cancer screening at either of the two VA sites.
- Patients who participate in lung cancer screening and are current smokers at the time of scheduling their screening exam.
Exclusion Criteria
- Providers who currently systematically prescribe cessation support medication to all current smokers will be excluded.
- Patients with urgent findings requiring biopsy/immediate attention on the screening CT will be excluded.
- Patients with a prior diagnosis of lung cancer or who are receiving active therapy for any cancer, except skin cancer, will be excluded.
- Patients previously diagnosed with cognitive impairment, dementia, or severe behavioral disorders, or have an indication in chart review of difficulty communicating or participating in telephone counseling sessions will be excluded.
Data sourced from ClinicalTrials.gov (NCT03612804). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.